缬沙坦和洛汀新对糖尿病肾病患者尿α_1-MG及β_2-MG的影响  

The Effect of Valsartan and Lotensin on the Urine α_1-MG and β_2-MG in Patients with Diabetic Nephrosis

作　　者：黄烈虎 叶荣[1] 林晰敏 

机构地区：[1]廉江市人民医院内分泌科,广东廉江524000

出　　处：《国际医药卫生导报》2004年第8期51-52,共2页International Medicine and Health Guidance News

摘　　要：　 目的　观察缬沙坦和洛汀新对糖尿病肾病患者尿α1-MG及β2-MG的影响,探讨不同药物应用对早期糖尿病肾病的保护作用。方法　46例2型糖尿病肾病患者,随机分为两组,缬沙坦组(23例)和洛汀新组(23例) ,分别给予缬沙坦和洛汀新治疗。于服药前及后4周、8周、12周测定患者尿α1-MG及β2-MG。结果　缬沙坦和洛汀新均能明显降低2型糖尿病患者尿α1-MG、β2-MG的排出,但缬沙坦的降低作用更显著(P<0.01)。结论　缬沙坦和洛汀新均能够阻止或延缓早期糖尿病肾病的发展,适用于糖尿病肾病患者,但缬沙坦的效果更佳。Objective To study the effect of valsartan and lotensin on urine α1 Microglobulin (α1-MG) and β2 Microglobulin (β2-MG) in type 2 diabetes mellitus (DM) with diabetic nephrosis (DN).Methods 46 cases of type 2 DM patients associated with hypertension and DN were divided into twogroups: valsartan group (n=23) and lotensin group (n=23). the urine α1 and β2 Microglobulin weremeasured before and after 4,8,12 weeks medication.Results Both valsartan and lotensin reduced α1-MG and β2-MG significantly(P<0.01).Conclusion Valsartan, just like lotensin, was suited to treatthe DN patients with increasingα1-MG and β2-MG excretion.

关 键 词：糖尿病肾病 缬沙坦 洛汀新 Α1-MG Β2-MG 

分 类 号：R587.1[医药卫生—内分泌]